Low-dose use of a treatment for certain advanced cancers, aldesleukin, was well-tolerated and lessened disease activity in people with refractory systemic lupus erythematosus (SLE) taking part in a small Phase 1/2a trial. Study results also showed patients had higher proportions of a subset of immune T-cells associated with suppression…
In support of projects in several areas of lupus research, the Lupus Foundation of America has awarded four investigators — two more  than in prior years — with the Gary S. Gilkeson Career Development Award (CDA). The award is meant for fellows and clinicians at the early stages of…
PredictImmune is planning to expand its pipeline with the development of new strategies to support personalized care for people with systemic lupus erythematosus (SLE) and other inflammatory diseases. This follows the U.K.-based company’s acquisition of worldwide licensing rights over Cambridge Enterprise’s algorithms and software. The new deal…
Researchers, in collaboration with the World Health Organization (WHO), have established a new reference standard for anti-dsDNA autoantibodies — one of the hallmarks of systemic lupus erythematosus (SLE) — to help standardize laboratory analysis and improve diagnosis and treatment of lupus worldwide. The study, “A WHO…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), recommended the approval of Benlysta (belimumab) as an add-on therapy for children age 5 and older with systemic lupus erythematosus (SLE) and high disease activity. The European Commission will…
Aiming to raise disease awareness and research funds, the Lupus Foundation of America’s (LFA) Walk to End Lupus Now hits Los Angeles on Sept. 28. Taking place at the LA Live complex, the 1.33-mile event will again feature actress Kate Linder of television’s “The Young and…
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Gazyva (obinutuzumab) for the treatment of adult patients with lupus nephritis, a life-threatening kidney inflammation. The breakthrough designation is given to medications that…
Reactivation of the Epstein-Barr virus (EBV) may result in systemic lupus erythematosus (SLE) in at-risk individuals, according to a study in relatives of SLE patients. The findings also revealed that gene variants previously associated with EBV infection are implicated in the risk of developing SLE. The research, “…
There is a strong need for multidisciplinary and specific research on childhood-onset systemic lupus erythematosus (SLE) to help better understand the condition and guide treatment, a study by the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Lupus Foundation of America…
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has been awarded a three-year $2.4-million grant from the U.S. Centers for Disease Control and Prevention (CDC), which will help efforts to understand the long-term outcomes of children and adolescents with lupus or other rheumatic diseases. The grant is meant…